Form 4: Hims & Hers Health CEO Andrew Dudum Exercises Options and Sells Shares
SEC Form 4 Filing
CEO Andrew Dudum exercised stock options and sold shares of Hims & Hers Health, Inc. on April 16, 2025, according to a Form 4 filing with the SEC.
Summary
- On April 16, 2025, Andrew Dudum, CEO of Hims & Hers Health, Inc., exercised stock options to acquire 33,668 shares of Class A Common Stock at an exercise price of $2.43.
- Dudum then sold 33,668 shares at an average price of $28.0213, 2,792 shares at an average price of $28.3066, and 47,534 shares at an average price of $28.2344.
- Following these transactions, Dudum directly owns 92,103 shares of Class A Common Stock.
- Dudum also indirectly owns a significant number of shares through various trusts, including the Dudum Family Community Property Trust, AD 2022 GRATs, Andrew Dudum 2015 Trust, AD 2021 GRATs, Dudum Family Heritage Trust, totaling several million shares.
- The reported transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 28, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing trading plan, with no clear positive or negative implications for the company's outlook.
Industry Context
Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future prospects. A pre-planned sale under Rule 10b5-1 is generally viewed as less indicative of management sentiment than discretionary trades.
Comparison to Industry Standards
- Comparing Andrew Dudum's transactions to other CEOs in the telehealth industry is difficult without specific data on their trading activity.
- However, it's common for CEOs to have a significant portion of their wealth tied to company stock and to periodically sell shares for diversification or personal financial planning.
- The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Stakeholder Impact
- The sale of shares by the CEO could create short-term selling pressure on the stock.
- However, the existence of a pre-arranged trading plan mitigates concerns about the CEO's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 2020-03-13 | Start date for vesting of stock options. |
| 2021 | Year of the Company's business combination transaction. |
| 2021-07-02 | Date of Andrew Dudum 2015 Trust. |
| 2021-08-10 | Date of Dudum Family Heritage Trust UAD. |
| 2021-11-01 | Date of AD 2021 GRAT and AD 2021 GRAT 2. |
| 2022-09-07 | Date of AD 2022 GRAT 2. |
| 2022-11-28 | Date of AD 2022 GRAT 3. |
| 2023-09-05 | Date of AD 2023 GRAT. |
| 2024-08-28 | Date the Rule 10b5-1 trading plan was adopted. |
| 2025-04-16 | Date of the reported transactions (option exercise and stock sales). |
| 2025-04-18 | Date of the Form 4 filing. |
| 2030-06-16 | Expiration date of the stock options. |
Keywords
Form 4, insider trading, stock options, Hims & Hers Health, Andrew Dudum, HIMS, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.